drug
as of 2026-07-01BI 425809 dose 3
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Boehringer Ingelheim
1 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
1
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia
NCT02832037Phase 2Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication